The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

This study is creating a collection of information (repository) about children and adults in the U.S. who have homozygous familial hypercholesterolemia (hoFH). This is a very rare condition where you inherit an abnormal gene from both parents, leading to very high cholesterol levels from birth. The goal is to better understand how hoFH affects health over time and how different treatments impact the arteries. Researchers will gather detailed medical information, including blood tests, heart evaluations, and imaging of your arteries. They will also collect information on treatments like statins, ezetimibe, LDL-apheresis, and liver transplant. This will help doctors learn the best ways to monitor and treat hoFH. To join, you must have hoFH, confirmed by very high LDL cholesterol levels (over 500 mg/dL) and/or genetic testing.

Study design
This is an observational study, meaning researchers will collect information without providing specific interventions. It aims to enroll 60 participants.
What's involved
Participants will undergo medical history and physical exams, blood tests, dietary evaluations, and cardiology evaluations including EKG, echocardiogram, and artery ultrasounds. Some may also have CT angiograms or other heart procedures. Medical photos of skin xanthomas and additional blood tests will also be taken.
Compensation
Not stated in the trial record.
Follow-up
The study will track changes in disease progression over 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01109368

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

Recruiting
Not specifiedAll AgesObservational
The Rogosin Institute
~60 participants
Updated 2026-04-06 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in disease progression
Measured over 10 years
Homozygous Familial Hypercholesterolemia
1 sites across 1 states
New York1
  • Lisa C. Hudgins, M.D. · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented, untreated fasting LDL cholesterol level of \> 500 mg/dL and triglycerides \< 200 mg/dL on a cholesterol-lowering diet for at least 8 weeks with secondary causes excluded, AND:
DNA confirmation of a double mutation of the LDL receptor or apoB gene OR
LDL \> 160 mg/dL in both biological parents not associated with a disorder know to elevate LDL OR
Coronary artery disease in one or both parents or grandparents \< 55 years for males, \< 65 for females OR
Tendinous/cutaneous xanthomas \< age 10 or coronary artery disease \< age 20
  • Change in disease progression10 years